Dthera Sciences helps Alzheimer’s disease through Artificial Intelligence
Digital therapeutic device is the first product to receive Breakthrough Device designation for Alzheimer’s from the FDA
Based on this approach, DTHR-ALZ, a digital therapeutic product, has been specially designed to treat the cognitive effects associated with Alzheimer’s disease, including anxiety and depression.
This therapeutic approach is oriented towards evidence-based behavioral intervention which uses Reminiscence therapy. Reminiscence therapy involves recalling memories of positive experiences from your past, from family outings to favorite songs to photos of past vacations.
Dthera Sciences seeks to include this type of technology within the algorithms and formal treatment scheme for neurodegenerative pathologies. This device could be considered the first non-pharmacological treatment prescribed for complicated neurodegenerative pathology. It represents a great advance in the medical field.
DTHR-ALZ is comprised of three key components:
- Custom computer tablet specifically designed and tested for seniors with Alzheimer’s disease
- Facial expression detection system to assess the reaction to reminiscence content
- Two sided AI that obtains and optimizes therapeutic content being delivered to the patient
The Food and Drug Administration (FDA) is an organization in charge of evaluating and approving medicines for use within the USA. With the advancement of digital technologies, the FDA has modernized existing regulations and created a whole new system of rules related to them known as The Breakthrough Devices program.
DTHR-ALZ is the first device in the Alzheimer’s field to receive the Breakthrough Device designation from the FDA. This designation allows scientists to advance product development faster for the benefit of patients.
Not only does the device improve the patient’s quality of life, but the largest organization related to the approval of therapeutic indications has recognized it as a useful and effective device.
This device can adjust each of its various programs through the integration of artificial intelligence, to optimize treatment. This is achieved through the feedback obtained from the patient, not through written reviews, but through detecting the patient’s expressions and adapting to their reactions.
Currently the final approvals and permits are in process and the device cannot be marketed in the United States, however, the future looks promising, not only for Dthera Sciences, but also for the patients it serves.
Learn more about Dthera Sciences: https://dthera.com